Published in J Viral Hepat on March 24, 2008
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials (1985) 6.22
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther (2012) 2.68
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat (2002) 1.71
Appropriateness of liver biopsy. Can J Gastroenterol (2000) 1.65
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol (2000) 1.61
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2014) 1.60
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing (1994) 1.56
Trends in primary liver cancer. Lancet (1998) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2001) 1.52
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis (1999) 1.45
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44
Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer. Parameters affecting long-term outcome. Dig Dis Sci (1990) 1.43
Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2002) 1.43
[CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study]. Gastroenterol Clin Biol (2001) 1.42
Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (1995) 1.41
[Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists]. Rev Med Interne (2013) 1.39
Endoscopic laser therapy for duodenal villous adenoma. Dig Dis Sci (1989) 1.38
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37
Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 1.33
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32
In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology (1997) 1.30
Fatigue in patients with chronic hepatitis C. J Viral Hepat (2002) 1.30
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci (1994) 1.26
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 1.26
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet (1995) 1.22
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology (2000) 1.21
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther (1998) 1.21
Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat (2007) 1.20
In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol (1997) 1.20
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol (1999) 1.19
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 1.14
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology (1999) 1.14
Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum. Am J Obstet Gynecol (1980) 1.10
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet (1998) 1.08
Systemic lupus erythematosus and chronic intestinal pseudoobstruction. J Rheumatol (1993) 1.08
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med (2013) 1.08
Gastric phytobezoar destruction by Nd:YAG laser therapy. Gastrointest Endosc (1986) 1.08
Portal hypertensive colopathy. A new entity. Dig Dis Sci (1991) 1.08
Computer-aided decision support in hepatology. Scand J Gastroenterol (1992) 1.07
Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat (2006) 1.06
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat (1999) 1.06
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.06
Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology (1986) 1.05
Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat (2002) 1.03
Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res (1988) 1.03
Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther (2006) 1.02
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat (2008) 1.02
Worsening of steatosis and fibrosis progression. Gut (2003) 1.01
Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. A randomized trial. J Hepatol (1988) 1.01
Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J Chronic Dis (1985) 1.00